Table 4.
Median (25th, 75th) concentration of anti-SARS-CoV-2 IgG-II antibodies in symptomatic SARS-CoV-2, 15–59 days after infection and asymptomatic individuals.
| Covariate | N (%) | Median (25th–75th) (AU/mL) | p |
|---|---|---|---|
| Overall | 180 (100.0) | 5088 (1050–12,620) | |
| Gender | 0.2691 | ||
| Male | 126 (70.0) | 5632 (1273–13,837) | |
| Female | 54 (30.0) | 3743 (883–11,187) | |
| Age (y) a | 0.0603 | ||
| 18–44 | 33 (19.1) | 1297 (296–7519) | |
| 45–54 | 30 (17.3) | 6577 (1601–16,623) | |
| 55–64 | 42 (24.3) | 6868 (2433–11,975) | |
| 65+ | 68 (39.3) | 5814 (1553–13,110) | |
| Hospitalization | <0.001 | ||
| No | 23 (12.8) | 808 (9–1668) | |
| Yes | 157 (87.2) | 6271 (1583–14,121) | |
| Asymptomatic | 0.0005 | ||
| No | 171 (95.0) | 5547 (1415–13,325) | |
| Yes | 9 (5.0) | 9 (<6.8–520) | |
| Severity b | 0.0001 | ||
| Mild | 60 (36.8) | 1634 (751–7868) | |
| Moderate | 39 (23.9) | 6082 (2433–9579) | |
| Severe | 17 (10.4) | 6638 (3053–13,837) | |
| Critical | 47 (28.8) | 11,975 (5318–23,351) | |
| Time from symptoms onset (days) c | 0.8887 | ||
| 15–29 | 82 (52.9) | 6980 (1060–14,968) | |
| 30–44 | 48 (31.0) | 6122 (2169–13,925) | |
| 45–59 | 25 (16.1) | 5452 (3306–9579) |
a Seven missing values, b Eight missing values, c Sixteen missing values. When grouped differently: Asymptomatic/mild: 1512 (452–6862) AU/mL and Moderate/Severe: 6360 (2895–12,137) AU/mL.